Age ≥2 years, oral solution 2.2 mg/mL: use the co-medication-specific table below. Without stiripentol: ceiling 0.35 mg/kg twice daily AND 26 mg/day. With stiripentol plus clobazam: ceiling 0.2 mg/kg twice daily AND 17 mg/day.
Pediatric
Same weight-based schedule from age 2; apply BOTH mg/kg and absolute daily caps. Renal/hepatic impairment or strong CYP1A2/CYP2D6 inhibitors can require lower caps.
Titration / repeat dosing
Without stiripentol: initial 0.1 → day 7 0.2 → day 14 0.35 mg/kg twice daily. With stiripentol plus clobazam: initial 0.1 → day 7 0.15 → day 14 0.2 mg/kg twice daily. For Dravet syndrome, increase according to response; for LGS, increase as tolerated to recommended maintenance.
Fintepla: co-medication-specific titration, age ≥2 years
Phase
Without stiripentol
With stiripentol + clobazam
Initial
0.1 mg/kg twice daily
0.1 mg/kg twice daily
Day 7
0.2 mg/kg twice daily
0.15 mg/kg twice daily
Day 14
0.35 mg/kg twice daily
0.2 mg/kg twice daily
Maximum total daily dose
26 mg/day AND weight-based ceiling
17 mg/day AND weight-based ceiling
Use the lower of the weight-based dose and absolute cap. Dravet syndrome: increase according to response; LGS: titrate as tolerated. Organ impairment and strong CYP inhibitors require separate limits.
Severe renal impairment (eGFR 15–29): maximum 20 mg/day without stiripentol or 17 mg/day with stiripentol plus clobazam; still respect the weight-based cap. End-stage renal disease is not studied.
Hepatic impairment
Without stiripentol: mild/moderate maximum 20 mg/day; severe 17 mg/day. With stiripentol plus clobazam: mild maximum 13 mg/day; moderate/severe not recommended. Respect weight-based ceilings.
Serum reference information
No established therapeutic range
Safety
Boxed warning
Valvular heart disease and pulmonary arterial hypertension; restricted FINTEPLA REMS program. Cases have been reported postmarketing despite none observed in DS/LGS clinical trials lasting up to 3 years (not all controlled trials).
Contraindications
Hypersensitivity; concomitant MAO inhibitors or use within the preceding 14 days.
Serious precautions & monitoring
Echocardiogram before treatment, every 6 months during treatment, and 3–6 months after the final dose. Monitor appetite, weight/growth, blood pressure and sedation; assess serotonin syndrome and glaucoma symptoms.
The 0.4 mg/kg/day group is not an intermediate exposure: stiripentol + clobazam increases fenfluramine exposure. Trial participants had Dravet syndrome; these rates are not LGS rates.
Human fenfluramine pregnancy data are insufficient to assess fetal risk. Animal studies found malformations, developmental loss and impaired growth with maternal toxicity at clinically relevant exposures.
Pregnancy / postpartum monitoring
Monitor maternal weight gain: fenfluramine can suppress appetite and cause weight loss.
Research summaries describe studied populations and outcomes; they do not add indications or constitute treatment recommendations.
Direct pivotal trial
Trial summary
Study design / duration
Randomized, double-blind, placebo-controlled Dravet syndrome studies used a 6-week baseline, 2-week titration, and 12–14-week maintenance; the Lennox-Gastaut syndrome study used a 4-week baseline and 14-week treatment.
Primary endpoint
Label primary result is model-derived difference relative to placebo, not median reduction: Dravet syndrome Study 1, −31.7% at 0.2 mg/kg/day and −70.0% at 0.7; Study 2 with stiripentol, −59.5% at 0.4. Ages 2–18; treatment 14/15 weeks.
Results
Dravet syndrome pivotal trials: median convulsive-seizure reductions were approximately 63–74% at 0.7 mg/kg/day versus 1–17% with placebo. Lennox-Gastaut syndrome trial: median drop-seizure reduction was 24% versus 7% with placebo.
Responder rate
Responder distributions are shown by regimen in label Figures 1–2; a single pooled percentage is not presented.
Seizure freedom
No convulsive seizures: Study 1 3/40 (8%) at 0.7 and 3/38 (8%) at 0.2 mg/kg/day vs 0 placebo over 14 weeks; Study 2 1/43 (2%) at 0.4 vs 0 over 15 weeks. Not all-seizure freedom.
Fenfluramine and active norfenfluramine exhibit serotonin 5-HT2 receptor agonist activity. The precise mechanism underlying seizure control is unknown.
Positive sigma-1 modulation by fenfluramine has been demonstrated in cellular and animal assays. This remains a proposed contribution, not a proven second clinical mechanism; parent and metabolite do not show identical sigma-1 effects.
5-HT2B-related pharmacology is relevant to valvular heart disease and pulmonary arterial hypertension risk; it must not be conflated with a demonstrated therapeutic target.
Former anorectic repurposed at lower doses for epilepsy; active metabolite is norfenfluramine.
Sources & review status
Indications and DailyMed PDFs checked: 2026-09-26. Other profile sources reviewed: 2026-09-15 · label revision noted at that review: 10/2025. This is a draft reference; final review is pending.